Učitavanje...
High cumulative doxorubicin dose for advanced soft tissue sarcoma
BACKGROUND: The recommended cumulative doxorubicin dose in soft tissue sarcoma (STS) treatment was based on cardiotoxicity data from retrospective studies of breast cancer patients. However, the treatment and prognosis of STS and breast cancer are quite different, and reference to breast cancer data...
Spremljeno u:
| Izdano u: | BMC Cancer |
|---|---|
| Glavni autori: | , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BioMed Central
2020
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7684756/ https://ncbi.nlm.nih.gov/pubmed/33228579 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-07663-x |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|